Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

HSI June 2026 Index Rebalance: Post-Announcement Positioning

HSI June 2026 Index Rebalance: Pre-Implementation Update

HSI Index Rebalance: March 2026 Post-Event Review

HSI Index Rebalance: Historical Patterns & March '25 Analysis

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Event-Driven

<ul>
<li>We review the HSLMI universe for potential candidates for the upcoming HSI May 2026 review.</li>
<li>Two stocks stand out as high-conviction candidates for index inclusion this cycle.</li>
<li>The rest of the shortlist looks more marginal and more dependent on committee discretion.</li>
</ul>


We review the HSLMI universe for potential candidates for the upcoming HSI May 2026 review.
Two stocks stand out as high-conviction candidates for index inclusion this cycle.
The rest of the shortlist looks more marginal and more dependent on committee discretion.


China Resources Mixc Lifestyle Services (1209 HK)

Contemporary Amperex Technology (3750 HK)

BeOne Medicines

HSI May 2026 Index Review Forecast